TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02009488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 100 mg
Description: One 100 mg capsule taken orally (by mouth) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 300 mg
Description: One 300 mg capsule taken orally (by mouth) once daily
Study: NCT02121808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume
Description: Tidal volume spontaneous ventilation, no assistance.
Study: NCT02009488

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule (inactive medication) once daily.
Study: NCT03275324

Intervention type: DEVICE
Intervention: Capnostream20p
Description: Observational study of patients connected to the Capnostream20p monitor.
Study: NCT03678311

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: If diagnosed with Long QT Syndrome and have Sleep Apnea index \>5 pauses per hour then given CPAP to wear for approximately 3 months.
Study: NCT03088527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD140
Description: RAD140 will be supplied as formulated drug-in-capsules for oral administration.
Study: NCT02135055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample collection
Description: Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample collection
Description: Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.
Study: NCT04274101

Intervention type: OTHER
Intervention: Clinical Manifestations
Description: Clinical manifestations in patients treated with Nifurtimox and Benznidazole

Intervention type: OTHER
Intervention: Clinical Manifestations
Description: Clinical manifestations in patients treated with Nifurtimox and Benznidazole
Study: NCT02135055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample collection
Description: Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample collection
Description: Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.
Study: NCT02985294

Intervention type: OTHER
Intervention: Multiple Excitability Measures of peripheral nerves
Description: The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and 'threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
Study: NCT02135055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sedation interruption
Description: Sedation interruption is performed at 8 am every morning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sedation interruption
Description: Sedation interruption is performed at 8 am every morning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sedation interruption
Description: Sedation interruption is performed at 8 am every morning.
Study: NCT04274101

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic response
Description: Serologic response in patients treated with Nifurtimox and Benznidazole

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic response
Description: Serologic response in patients treated with Nifurtimox and Benznidazole

Intervention type: DIAGNOSTIC_TEST
Intervention: Direct method
Description: Direct method tests in patients treated with Nifurtimox and Benznidazole

Intervention type: DIAGNOSTIC_TEST
Intervention: Direct method
Description: Direct method tests in patients treated with Nifurtimox and Benznidazole
Study: NCT02135055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sedation interruption
Description: Sedation interruption is performed at 8 am every morning.
Study: NCT04274101

Intervention type: BEHAVIORAL
Intervention: Adverse events
Description: Adverse events in patients treated with Nifurtimox and Benznidazole

Intervention type: BEHAVIORAL
Intervention: Adverse events
Description: Adverse events in patients treated with Nifurtimox and Benznidazole
Study: NCT02884089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study: NCT03333707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pacifica App
Description: The app contains several activities which are digital implementations of standard psychotherapy practices. Users may select which app elements they would like to use, and when. These app elements include relaxation and meditation activities, tools to examine your thoughts or self-talk, goal setting lists, and mood and health ratings. The app also has a peer support community where users can communicate with others who are having similar experiences. There is no minimum requirement for amount of time spent on any given activity, or in the app in total. The commercially available app has a feature to connect users to their existing healthcare providers, but this feature will not be available to study participants. Study participants may continue to see their existing providers.
Study: NCT00554788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation
Description: Undergo peripheral blood stem cell or bone marrow transplant
Study: NCT01633788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-195263 0.1%
Description: 1 drop of AGN-195263 0.1% instilled in each eye twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-195263 0.03%
Description: 1 drop of AGN-195263 0.03% instilled in each eye twice daily.
Study: NCT00554788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo peripheral blood stem cell or bone marrow transplant
Study: NCT01633788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-195263 0.01%
Description: 1 drop of AGN-195263 0.01% instilled in each eye twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-195263 Vehicle
Description: 1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
Study: NCT00554788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT02754921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous dilatational tracheostomy using Ultra-Perc
Description: Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ultra-Perc

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
Description: Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
Study: NCT02399709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00760682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
Study: NCT03857100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audit and feedback - letter and report
Description: letter describing project and report of participants' outlier status and how participants compare to peers
Study: NCT04374461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours. Patients are also eligible to restart N-acetylcysteine treatment on the same treatment arm without reconsent if they are within the 30 day followup period after their prior course of treatment on this protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours. Patients are also eligible to restart N-acetylcysteine treatment on the same treatment arm without reconsent if they are within the 30 day followup period after their prior course of treatment on this protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Blood
Description: A total of 16mL of research whole blood will be collected in CPT tubes at baseline, Cycle 2 Day 1 (or as close as feasible, when still coordinating sample collection across patients in a critical-care unit), and at end of study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Blood
Description: A total of 16mL of research whole blood will be collected in CPT tubes at baseline, Cycle 2 Day 1 (or as close as feasible, when still coordinating sample collection across patients in a critical-care unit), and at end of study.
Study: NCT00554788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT06376578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Exercise training will progress incrementally, increasing the duration of exercise on the treadmill by 5 minutes every 2 weeks whereby the final duration on the treadmill will be 35 minutes and the total duration will map onto recommended guidelines of 150 minutes per week. Throughout the 8-weeks, the duration of exercise on the cycle ergometer will remain at 15 minutes. Exercise intensity will progress throughout the 8-week intervention on both the treadmill and the cycle ergometer by 5% every 2 weeks, whereby exercise during the final week will be at 70% VO2max.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polar A380 wristwatch physical activity tracker
Description: The research team will monitor individual exercise training weekly using virtual/electronic methods and a 30 minute telephone call. The researcher will provide feedback about how the participant's activity compares to physical activity recommendations, and encouragement and support will be provided verbally.
Study: NCT02297386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] DIHYDRO-TESTOSTERONE
Study: NCT00554788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell or bone marrow transplant

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02297386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET scan
Study: NCT00617266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tobacco cessation intervention
Description: Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
Study: NCT02297386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Study: NCT02484755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: See Arm Description
Study: NCT01662323

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GP's treating HF according the dutch guidelines

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GP's treating HF according the dutch guidelines
Study: NCT01934491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training A

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training B
Study: NCT01806142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides
Description: During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn oil
Description: During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
Study: NCT02611817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC 108 mg
Description: Vedolizumab SC Injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vedolizumab placebo-matching SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab IV 300 mg
Description: Vedolizumab IV Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV 300 mg
Description: Vedolizumab IV Injection.
Study: NCT00617266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco cessation intervention
Description: Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco cessation intervention
Description: Distribution of pamphlets containing information on the hazards of tobacco

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco cessation intervention
Description: Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
Study: NCT00077766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).
Study: NCT00721513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study: NCT00238108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02843490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
Study: NCT01546701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 2 mg sublingual tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.1 mg/kg IV morphine
Study: NCT01108861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE VIABAHN® Endoprosthesis
Description: GORE VIABAHN® Endoprosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain old balloon angioplasty
Description: Plain old balloon angioplasty
Study: NCT03988049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1,550 fracionated photothermolysis laser
Description: All subjects will have one side of their face treated with one laser, and the other side with the other laser.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 755 picosecond laser
Description: All subjects will have one side of their face treated with one laser, and the other side with the other laser.
Study: NCT03382691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood pressure check
Description: Check blood pressure using new device and conventional device alternatively. Compare blood pressure measured with new device and conventional device.
Study: NCT04013373

Intervention type: DEVICE
Intervention: SOZO Bioimpedance Spectroscopy Device
Description: Bioimpedance spectroscopy measurements for assessment of fluid status
Study: NCT02685306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: 12 weekly doses of bavituximab given on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane
Description: 12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
Study: NCT00449761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT04401046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later
Description: The first survey will include questions relative to sociodemographic characteristics, existence of psychological troubles; living conditions in the Covid19 pandemic context; IES-R, Stait Trait Anxiety, and the fear of a cancer recurrence scales, satisfaction with cancer care and medical status of patients (diagnosis, ongoing treatment, follow-up of the disease).
Study: NCT00761085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Standard of care for pain management of acute episode of pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Standard of care for pain management of acute episode of pain
Study: NCT02121808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume
Description: Tidal volume spontaneous ventilation, no assistance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume
Description: Tidal volume spontaneous ventilation, no assistance.
Study: NCT00761085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Compare to standard of care for pain management of acute episode of pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Compare to standard of care for pain management of acute episode of pain
Study: NCT02685306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: 12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78